Clusters of differentiation

Positive Findings From Phase 1b Trial of GlycoMimetics’ GMI-1359 To Be Presented at AACR 2021 Meeting

Retrieved on: 
Saturday, April 10, 2021

The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually on April 10-15 and May 17-21.

Key Points: 
  • The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually on April 10-15 and May 17-21.
  • The clinical poster concludes that GMI-1359 demonstrated an acceptable safety and tolerability profile in the patients treated to date.
  • These findings on immune cell redistributions strongly suggest the induction of a more favorable anti-tumor environment following GMI-1359 administration.
  • GlycoMimetics has an ongoing Phase 1b clinical trial evaluating its wholly-owned drug candidate GMI-1359, a combined CXCR4 and E-selectin antagonist.

New Clinical Responses for AGEN1181 Presented at AACR

Retrieved on: 
Saturday, April 10, 2021

AGEN1181 is showing activity in patients with tumors which typically do not respond to first-generation CTLA-4 and PD-1 antibodies.

Key Points: 
  • AGEN1181 is showing activity in patients with tumors which typically do not respond to first-generation CTLA-4 and PD-1 antibodies.
  • In two separate presentations at AACR, Agenus showcased the optimal performance of AGEN1181 in relevant models.
  • In addition, as the clinical data matures, additional responses as well as a conversion from a partial response to a complete response, have been observed.
  • The new data announced today include the following clinical responses:
    E-poster presentations were made available on the conference platform on April 10 at 8:30am ET.

TCR² Highlights Gavo-cel Translational Data and Emerging Solid Tumor Pipeline Preclinical Data at AACR Annual Meeting

Retrieved on: 
Saturday, April 10, 2021

In addition, preclinical data from the Companys autologous CD70 and allogeneic mesothelin TRuC-T cells will be highlighted in e-posters in the Adoptive Cell Therapy session at AACR.

Key Points: 
  • In addition, preclinical data from the Companys autologous CD70 and allogeneic mesothelin TRuC-T cells will be highlighted in e-posters in the Adoptive Cell Therapy session at AACR.
  • Translational data highlights from the poster include:
    CD4:CD8 Ratio: The median CD4:CD8 ratio in the gavo-cel T cell products was 7.15.
  • We look forward to providing further updates on our solid tumor pipeline throughout the year.
  • Any forward-looking statement included in this press release speaks only as of the date on which it was made.

GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma Model

Retrieved on: 
Saturday, April 10, 2021

The study demonstrates that GMI-1757 significantly improved anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model.

Key Points: 
  • The study demonstrates that GMI-1757 significantly improved anti-PD-L1 therapeutic activity in a pancreatic adenocarcinoma model.
  • Microscopic evaluations also showed that in groups treated with GMI-1757 both the incidence and area of intratumoral fibrosis were markedly reduced.
  • Investigations will continue on GMI-1757s impact when combined with immune modulators where fibrosis and restricted host cell infiltration negatively impact tumor response.
  • GlycoMimetics has an ongoing Phase 1b clinical trial evaluating its wholly-owned drug candidate GMI-1359, a combined CXCR4 and E-selectin antagonist.

Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates

Retrieved on: 
Friday, April 9, 2021

For MET/SRC/CSF1R inhibitor TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.

Key Points: 
  • For MET/SRC/CSF1R inhibitor TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.
  • With the new data, Turning Point is evaluating a potential additional combination study of TPX-0022 and an anti-PD-1 checkpoint inhibitor.
  • Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics drug candidates, the results, conduct, progress and timing of Turning Point Therapeutics pre-clinical studies and plans regarding future development activities.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, April 9, 2021

MOUNTAIN VIEW, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Companys orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR).

Key Points: 
  • MOUNTAIN VIEW, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Companys orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR).
  • The poster presentation, which showcases CCX559s ability to induce anti-tumor immunity, will go live on Saturday, April 10 at 8:30 a.m.
  • PD-L1/PD-1 interaction is one of the major checkpoints that limit effector T cell function against cancer cells.
  • The study featured in the AACR poster presentation demonstrated that CCX559 potentially employs distinct mechanisms to inhibit PD-L1 compared to the anti-human PD-L1 antibodies.

Clinical Data with ImCheck’s ICT01 to be Presented at AACR: Positive Results Observed on Safety, Activation of Gamma 9 Delta 2 T Cells and Anti-tumor Immune Response

Retrieved on: 
Friday, April 9, 2021

The ongoing EVICTION trial is evaluating ICT01 in patients with advanced, relapsed/refractory solid and hematologic cancers with no remaining standard of care.

Key Points: 
  • The ongoing EVICTION trial is evaluating ICT01 in patients with advanced, relapsed/refractory solid and hematologic cancers with no remaining standard of care.
  • Across the cohorts treated, more than 95% of 92 T cells migrated out of the circulation at all four ICT01 doses.
  • BTN3A is essential for the activation of the anti-tumor immune response of 92 T cells.
  • In addition, preclinical experiments with ImChecks antagonist antibodies have shown their potential as treatments for a wide range of autoimmune diseases.

I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors

Retrieved on: 
Tuesday, April 6, 2021

Using ABLs Grabody-T bispecific antibody platform technology, TJ-L14B/ABL503 stimulates 4-1BB activation only in the presence of PD-L1 expressing tumor cells to minimize the risk of off-tumor toxicity.

Key Points: 
  • Using ABLs Grabody-T bispecific antibody platform technology, TJ-L14B/ABL503 stimulates 4-1BB activation only in the presence of PD-L1 expressing tumor cells to minimize the risk of off-tumor toxicity.
  • Preclinical studies have demonstrated that the bispecific antibody shows better anti-tumor activity than equimolar doses of single agents alone or in combination.
  • Co-targeting of PD-L1 with a bispecific antibody molecule using this particular platform is postulated to enhance antitumor activity while ensuring the safety of the patients.
  • ABL Bio, Inc. (Kosdaq: 298380) is a South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases.

Teon Therapeutics to Present Preclinical Proof of Concept Data at American Association for Cancer Research (AACR) Conference

Retrieved on: 
Monday, April 5, 2021

Details relating to the presentation are as follows:

Key Points: 
  • Details relating to the presentation are as follows:
    "We are pleased that the first public presentation of our TT-702 will occur at the AACR Annual Meeting," stated Peter Fan, Ph.D., Co-founder, Vice President of Biology at Teon Therapeutics.
  • "TT-702 is a selective and potent small molecule A2B receptor antagonist that not only improves antitumor immunity, but also inhibits cancer cell proliferation.
  • It can convert cold tumors into immunologically hot tumors and enables the effect of anti-PD-1 in cold tumors."
  • For more information about Teon Therapeutics, please visit: www.teontherapeutics.com
    View original content to download multimedia: http://www.prnewswire.com/news-releases/teon-therapeutics-to-present-pre...

Molecular Templates to Prioritize Next-Generation ETB Candidates

Retrieved on: 
Monday, April 5, 2021

In addition, MTEM announced the decision to discontinue development of MT-3724, MTEMs only first-generation ETB.

Key Points: 
  • In addition, MTEM announced the decision to discontinue development of MT-3724, MTEMs only first-generation ETB.
  • MTEM will focus on the clinical development of next-generation ETBs MT-5111, TAK-169, and MT-6402, as well as advancing next-generation preclinical ETB candidates against targets including CTLA-4, CD20, SLAMF-7 and CD45.
  • Takeda has communicated that its decision to turn over full rights of TAK-169, a second-generation ETB targeting CD38, wasthe result of Takedas ongoing portfolio prioritization.
  • Molecular Templates is a clinical-stage company focused on the discovery and development of targeted biologic therapeutics.